US FDA shows flexibility on unapproved opioids ban
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration, as it moves ahead with its initiative to ensure that all drugs available on the market meet required standards for safety and efficacy, has temporarily allowed seven companies to continue the marketing and distribution of an unapproved opioid drug1. The drug in question is a high-concentrate morphine sulfate oral solution that is widely used to alleviate pain in terminally ill patients.